Pallone, Maloney Push FDA For More Info On Aduhelm’s Revew, Approval

By Beth Wang / September 2, 2021 at 6:52 PM
Key House committee leaders sent a letter to acting FDA chief Janet Woodcock demanding the agency provide additional information about the review and approval of Biogen’s controversial Alzheimer’s drug Aduhelm, as they’re concerned by “apparent anomalies” in FDA’s review process and by reports of unusual coordination between FDA and Biogen throughout the drug’s approval process. The information is a key part of the lawmakers’ ongoing investigation into Aduhelm’s approval and cost. FDA and Biogen have come under fire ever since...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.